• Medientyp: E-Artikel
  • Titel: The shed P2X7 receptor is an index of adverse clinical outcome in COVID-19 patients
  • Beteiligte: Vultaggio-Poma, Valentina; Sanz, Juana Maria; Amico, Andrea; Violi, Alessandra; Ghisellini, Sara; Pizzicotti, Stefano; Passaro, Angelina; Papi, Alberto; Libanore, Marco; Di Virgilio, Francesco; Giuliani, Anna Lisa
  • Erschienen: Frontiers Media SA, 2023
  • Erschienen in: Frontiers in Immunology
  • Sprache: Nicht zu entscheiden
  • DOI: 10.3389/fimmu.2023.1182454
  • ISSN: 1664-3224
  • Schlagwörter: Immunology ; Immunology and Allergy
  • Entstehung:
  • Anmerkungen:
  • Beschreibung: <jats:sec><jats:title>Introduction</jats:title><jats:p>The pathophysiology of the Corona Virus Disease 2019 (COVID-19) is incompletely known. A robust inflammatory response caused by viral replication is a main cause of the acute lung and multiorgan injury observed in critical patients. Inflammasomes are likely players in COVID-19 pathogenesis. The P2X7 receptor (P2X7R), a plasma membrane ATP-gated ion channel, is a main activator of the NLRP3 inflammasome, of the ensuing release of inflammatory cytokines and of cell death by pyroptosis. The P2X7R has been implicated in COVID-19-dependent hyperinflammation and in the associated multiorgan damage. Shed P2X7R (sP2X7R) and shed NLRP3 (sNLRP3) have been detected in plasma and other body fluids, especially during infection and inflammation.</jats:p></jats:sec><jats:sec><jats:title>Methods</jats:title><jats:p>Blood samples from 96 patients with confirmed SARS-CoV-2 infection with various degrees of disease severity were tested at the time of diagnosis at hospital admission. Standard haematological parameters and IL-6, IL-10, IL-1β, sP2X7R and sNLRP3 levels were measured, compared to reference values, statistically validated, and correlated to clinical outcome. </jats:p></jats:sec><jats:sec><jats:title>Results</jats:title><jats:p>Most COVID-19 patients included in this study had lymphopenia, eosinopenia, neutrophilia, increased inflammatory and coagulation indexes, and augmented sNLRP3, IL-6 and IL-10 levels. Blood concentration of sP2X7R was also increased, and significantly positively correlated with lymphopenia, procalcitonin (PCT), IL-10, and alanine transaminase (ALT). Patients with increased sP2X7R levels at diagnosis also showed fever and respiratory symptoms, were more often transferred to Pneumology division, required mechanical ventilation, and had a higher likelihood to die during hospitalization. </jats:p></jats:sec><jats:sec><jats:title>Conclusion</jats:title><jats:p>Blood sP2X7R was elevated in the early phases of COVID-19 and predicted an adverse clinical outcome. It is suggested that sP2X7R might be a useful marker of disease progression.</jats:p></jats:sec>
  • Zugangsstatus: Freier Zugang